Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Takeda And enGene Establish Strategic Alliance to Develop Novel Therapeutics For Gastrointestinal Diseases
January 12, 2016
Osaka, Japan, and Montreal, Canada - Takeda Pharmaceutical Company Ltd. (TSE: 4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGenes Gene Pill gene delivery platform. The strategic alliance will leverage enGenes expertise and intellectual property position in delivering therapeutic genes to cells of the gut lining by using its proprietary non-viral vector platform.
Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda through pre-clinical proof of concept and IND enabling studies. At that point, Takeda will have an option to exclusively license the global rights for the product candidates.
Following option exercise, Takeda will be responsible for all clinical development and commercialization of those products. enGene will receive an upfront payment and reimbursement of all R&D costs incurred during the development of the selected targets. In addition, enGene is eligible to earn milestone payments for the product candidates based on accomplishment of specific research, clinical, regulatory and commercial milestones. enGene also will receive tiered royalties on future net sales of the collaboration products. Further details of the agreement were not disclosed.
Takeda will also collaborate with enGene in developing Gene Pill into a platform for oral delivery of antibodies. Takeda has the exclusive option to obtain a right of first negotiation for up to three antibody targets.
We aim to have a positive impact on patients lives by translating unique innovations in science into life-changing medicines to treat GI disorders, said Gareth Hicks, who leads gastroenterology discovery research at Takeda. Therefore, we are pleased to partner with enGene to further investigate the potential of their Gene Pill delivery platform.
We are very excited to be collaborating with the team at Takeda to investigate new medicines for the specialty GI market using enGenes innovative gene delivery platform for the gut, said Dr. Anthony T. Cheung, chief executive officer and a co-founder of enGene. In addition to gaining non-dilutive funding to support the development of our own products, this alliance provides our company an excellent opportunity to grow our drug development capabilities through working with a leading pharmaceutical company in the gastroenterology space.
About enGene, Inc.
enGene Inc. is a privately held biotechnology company developing a versatile, proprietary non-viralvector platform for gene delivery to mucosal cells lining the gut. The vector system can be administered to the intestine via the oral or enema route. enGene is developing its unique gene delivery formulation into an orally available Gene Pill, which has the potential to be a platform for oral delivery of a wide range protein drugs. Its primary focus is targeting its technology to enable localize delivery of immune-modulating proteins to the gut for treating various immune disorders.
Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Additional information about Takeda is available through its corporate website, www.takeda.com.